# OnCo record ovarian (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ovarian/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ovarian" ;
  schema:name "Ovarian cancer"@en ;
  schema:alternateName "OV"@en, "TCGA-OV"@en, "ovarian serous cystadenocarcinoma (TCGA OV cohort)"@en, "Fallopian Tube Cancer"@en, "Primary Peritoneal Cancer"@en ;
  schema:description "Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."@en ;
  schema:url <https://onco.cc/cancers/ovarian/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q172341> ;
  schema:citation <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  onco:tag "gyn", "spike" ;
  onco:related <https://onco.cc/pairings/parp-plus-bevacizumab/>, <https://onco.cc/pairings/hipec-at-interval-surgery/>, <https://onco.cc/pairings/caution-pd1-first-line-ovarian/>, <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/collections/ovarian-cancer-research-alliance/>, <https://onco.cc/cancers/paediatric-germ-cell-tumours/>, <https://onco.cc/ideas/idea-targeting-aneuploidy/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/synthetic-lethality-approaches/>, <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/risk-reducing-salpingectomy/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/robotic-surgery/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/targets/cdh6/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/targets/atr/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/mesothelin/>, <https://onco.cc/targets/cldn6/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/amifostine/>, <https://onco.cc/drugs/talc-sclerosant/>, <https://onco.cc/drugs/catumaxomab/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/scancell/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/gsk/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/corcept/>, <https://onco.cc/companies/verastem/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/sutro-biopharma/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/ca-125/>, <https://onco.cc/terms/lgsoc/>, <https://onco.cc/terms/hgsoc/>, <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/nct04498117/>, <https://onco.cc/trials/nct06394492/>, <https://onco.cc/trials/nct06834672/>, <https://onco.cc/trials/nct06855069/>, <https://onco.cc/trials/nct07214779/>, <https://onco.cc/trials/nct07546500/>, <https://onco.cc/trials/nct05281471/>, <https://onco.cc/trials/nct04169997/>, <https://onco.cc/trials/nct07218809/>, <https://onco.cc/trials/nct07213804/>, <https://onco.cc/trials/nct04921527/>, <https://onco.cc/trials/nct03949283/>, <https://onco.cc/trials/nct07109414/>, <https://onco.cc/trials/nct06828354/>, <https://onco.cc/trials/nct05445778/>, <https://onco.cc/trials/nct04884360/>, <https://onco.cc/trials/nct07219238/>, <https://onco.cc/trials/nct07318558/>, <https://onco.cc/trials/nct06994195/>, <https://onco.cc/trials/nct06824467/>, <https://onco.cc/trials/nct06072781/>, <https://onco.cc/trials/nct05804370/>, <https://onco.cc/trials/nct07604766/>, <https://onco.cc/trials/nct06819007/>, <https://onco.cc/trials/nct04421963/>, <https://onco.cc/trials/nct06619236/>, <https://onco.cc/trials/nct07225270/>, <https://onco.cc/trials/nct06915025/>, <https://onco.cc/trials/nct07564141/>, <https://onco.cc/trials/nct01874353/>, <https://onco.cc/trials/nct03602859/>, <https://onco.cc/trials/nct07286266/> ;
  onco:people <https://onco.cc/people/robert-coleman/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-brca-risk-reducing-surgery-jama-2010/> ;
  onco:journals <https://onco.cc/journals/international-journal-of-gynecological-cancer/>, <https://onco.cc/journals/journal-of-gynecologic-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/raludotatug-deruxtecan/>, <https://onco.cc/drugs/puxitatug-samrotecan/>, <https://onco.cc/technologies/parp-pet/>, <https://onco.cc/drugs/galleri/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/in10018/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/oregovomab/>, <https://onco.cc/drugs/hlx43/>, <https://onco.cc/drugs/shr-a1921/>, <https://onco.cc/drugs/ibi354/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/hs-20089/>, <https://onco.cc/drugs/incb123667/>, <https://onco.cc/drugs/azenosertib/>, <https://onco.cc/drugs/olvimulogene-nanivacirepvec/>, <https://onco.cc/drugs/imp4927/>, <https://onco.cc/drugs/azd5335/>, <https://onco.cc/drugs/sofetabart-mipitecan/>, <https://onco.cc/drugs/chiauranib/>, <https://onco.cc/drugs/avzo-021/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/lorigerlimab/>, <https://onco.cc/drugs/utomilumab/>, <https://onco.cc/drugs/azd8421/>, <https://onco.cc/drugs/tilt-123/>, <https://onco.cc/drugs/pamiparib/>, <https://onco.cc/drugs/cyh33/>, <https://onco.cc/drugs/vudalimab/>, <https://onco.cc/drugs/upifitamab-rilsodotin/>, <https://onco.cc/drugs/theo-260/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/drugs/nuv-1511/>, <https://onco.cc/drugs/rinatabart-sesutecan/>, <https://onco.cc/trials/rainfol-01/>, <https://onco.cc/drugs/luveltamab-tazevibulin/>, <https://onco.cc/trials/rejoice-ovarian01/>, <https://onco.cc/drugs/avutometinib-defactinib/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/targets/atr/>, <https://onco.cc/technologies/risk-reducing-salpingectomy/>, <https://onco.cc/ideas/idea-fra-adc-sequencing-ovarian/>, <https://onco.cc/ideas/idea-ctdna-guided-parp-duration/> ;
  onco:standardOfCare <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/drugs/relacorilant/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/risk-reducing-salpingectomy/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/trials/ukctocs/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/trials/ovhipec-1/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/gog-0218-icon7/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/solo-1/>, <https://onco.cc/trials/paola-1/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/prima/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/paola-1/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/pairings/parp-plus-bevacizumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/prima/>, <https://onco.cc/trials/desktop-iii/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/trials/mirasol/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/keynote-b96/>, <https://onco.cc/drugs/relacorilant/>, <https://onco.cc/trials/rosella/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/rinatabart-sesutecan/>, <https://onco.cc/drugs/raludotatug-deruxtecan/>, <https://onco.cc/trials/aurelia/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/avutometinib-defactinib/>, <https://onco.cc/trials/ramp-201/>, <https://onco.cc/terms/lgsoc/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/checkpoint-inhibitor/> .